½ÃÀ庸°í¼­
»óÇ°ÄÚµå
1574783

¼¼°èÀÇ µð¾Æº£¸®µò ½ÃÀå : Á¦Ç° À¯Çü, ¿ëµµ, ÃÖÁ¾ »ç¿ëÀÚ, À¯Åë ä³Îº° ¿¹Ãø(2025-2030³â)

Diaveridine Market by Product Type (Liquid Form, Solid Form), Application (Human Medicine, Veterinary Medicine), End User, Distribution Channel - Global Forecast 2025-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: 360iResearch | ÆäÀÌÁö Á¤º¸: ¿µ¹® 199 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

µð¾Æº£¸®µò ½ÃÀåÀº 2023³â¿¡ 2¾ï 3,445¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í, 2024³â¿¡´Â 2¾ï 5,538¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR) 9.35%·Î ¼ºÀåÇÏ¿©, 2030³â¿¡´Â 4¾ï 3,849¸¸ ´Þ·¯¿¡ À̸¦°ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

µð¾Æº£¸®µòÀº ÁÖ·Î °¡ÃàÀÇ Ç׿øÃæÁ¦·Î¼­ »ç¿ëµÇ´Â µ¿¹°¿ë ÀǾàÇ°À¸·Î, ±â»ýÃæÀÇ ¿±»ê ÇÕ¼ºÀ» ÀúÇØÇÔÀ¸·Î½á Ä۽õãÁõ µîÀÇ ¿øÃæ °¨¿°Áõ¿¡ È¿°ú¸¦ ¹ßÈÖÇØ, µ¿¹°ÀÇ °Ç°­¿¡ Áß¿äÇÑ ¿ªÇÒÀ» °ú¿¬. µð¾Æº£¸®µòÀÇ Çʿ伺Àº °¡ÃàÀÇ °Ç°­°ú »ý»ê¼ºÀ» À¯ÁöÇÏ´Â ÀÓ¹ÚÇÑ ÇÊ¿ä·Î ÀÎÇØ ¹ß»ýÇÕ´Ï´Ù. ±× ¿ëµµ´Â °¡±Ý·ù, µÅÁö, ¼ÒÀÇ °¢ »ê¾÷¿¡ °ÉÃÄ, ³ó°¡³ª ¼öÀÇ»ç´Â ¿øÃ溴À» ¿¹¹æ, °ü¸®ÇÏ°í, ÃÖÁ¾ÀûÀ¸·Î´Â È¿À²ÀûÀÎ ½ÄÀ°, ³«³ó »ý»êÀ» È®º¸Çϱâ À§Çؼ­ ÀÌ Á¦Ç°À» ÀÇÁöÇÏ°í ÀÖ´Ù ÇÕ´Ï´Ù. ÃÖÁ¾ ¿ëµµÀÇ ¹üÀ§´Â ºÏ¹Ì, À¯·´, APAC, ƯÈ÷ ±Þ¼ÓÇÑ µµ½ÃÈ­°¡ ½ÄÀ° ¼Òºñ¿¡ ¹ÚÂ÷¸¦ °¡ÇÏ°í ÀÖ´Â Áß±¹°ú Àεµ µî Áý¾àÀûÀÎ Ãà»êÀÌ ÀÌ·ç¾îÁö°í ÀÖ´Â Áö¿ª¿¡¼­ ƯÈ÷ ±¤´ëÇÕ´Ï´Ù.

ÁÖ¿ä ½ÃÀå Åë°è
±âÁسâ(2023) 2¾ï 3,445¸¸ ´Þ·¯
¿¹Ãø³â(2024) 2¾ï 5,538¸¸ ´Þ·¯
¿¹Ãø³â(2030) 4¾ï 3,849¸¸ ´Þ·¯
º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR)(%) 9.35%

½ÃÀå ÀλçÀÌÆ®¿¡ µû¸£¸é, µð¾Æº£¸®µò ½ÃÀåÀÇ ¼ºÀå¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ÁÖ¿ä ¿äÀÎÀ¸·Î´Â ±ÞÁõÇÏ´Â ¼¼°èÀÇ ½ÄÀ° ¼ö¿ä, ¼öÀÇÇÐÀÇ Áøº¸, µ¿¹° º¹Áö¿¡ ´ëÇÑ ÀÇ½Ä Áõ°¡ µîÀÌ ÀÖ½À´Ï´Ù. ¶ÇÇÑ ³ó¾÷ÀÇ ±â¼ú ÅëÇÕÀº Á¤È®ÇÑ ¾à¹° Åõ¿©¸¦ Áö¿øÇÏ°í È¿´É°ú º¹¿ë·® »ç¾ç Áؼö¸¦ °­È­ÇÕ´Ï´Ù. ÇöÀç, ÀáÀçÀûÀÎ ºñÁî´Ï½º ±âȸ´Â ¾à¹° ³»¼º°ú ½Î¿ì±â À§ÇØ ´Ù¸¥ ¾à¹°°ú °áÇÕÇÏ´Â Á¦ÇüÀÇ Æ÷Æ®Æú¸®¿À¸¦ È®´ëÇÏ´Â °Í°ú ´ú »ç¿ëµÇ´Â Ãà»ê ºÐ¾ß¿¡¼­ÀÇ ÀÌÁ¡À» ã´Â °ÍÀÔ´Ï´Ù. ÀÌ·¯ÇÑ °úÁ¦¸¦ ±Øº¹Çϱâ À§Çؼ­´Â ¿¬±¸°³¹ß¿¡ ´ëÇÑ ÅõÀÚ¿Í ³ó¾÷ °ü·Ã±â°ü°úÀÇ ÆÄÆ®³Ê½Ê ±¸ÃàÀÌ ÇÊ¿äÇÏ°í, ³»¼ºÀÇ °úÁ¦¸¦ ÇØ°áÇÏ°í ½Ã³ÊÁö È¿°ú¸¦ ¹ßÈÖÇÏ´Â ¼Ö·ç¼ÇÀ» Çõ½ÅÇÒ ÇÊ¿ä°¡ ÀÖ½À´Ï´Ù.

±×·¯³ª ½ÃÀåÀÇ ¼ºÀåÀº ¾ö°ÝÇÑ ±ÔÁ¦°ü¸®¿Í °øÁߺ¸°Ç ¿ì·Á¿¡ ÀÇÇØ ¾ïÁ¦µÇ°í ÀÖÀ¸¸ç, Ç×±ÕÁ¦ ³»¼ºÀº Å« ÁÖ¸ñÀ» ¹Þ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ À¯±â³ó°ú Ç×»ýÁ¦¸¦ »ç¿ëÇÏÁö ¾Ê´Â ½ÄÀ°À» ¿ä±¸ÇÏ´Â ¼ÒºñÀÚ µ¿Çâ Áõ°¡°¡ °úÁ¦°¡µÇ°í ÀÖ½À´Ï´Ù. Diaveridine ½ÃÀåÀÇ Çõ½ÅÀº Áö¼Ó °¡´ÉÇÑ ¾à¹° Á¦Á¦, Èí¼ö¼ºÀ» Çâ»ó½ÃÅ°´Â ¸¶ÀÌÅ©·Î ĸ½¶È­, À¯±â ³ó¾÷ ±ÔÁ¤À» ÁؼöÇÏ´Â ¹ÙÀÌ¿À ´ëüǰ¿¡ ÁßÁ¡À» µÑ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¿ªÇÐÀ» ÀÌÇØÇÏ´Â °ÍÀº ±ÔÁ¦ »óȲ°ú ¼ÒºñÀÚ ¼±È£µµÀÇ ÁøÈ­¸¦ Ư¡À¸·Î ÇÏ´Â °æÀï ½ÃÀå¿¡¼­ ¹ßÆÇÀ» È®º¸ÇÏ´Â °ÍÀ» ¸ñÇ¥·Î ÇÏ´Â ±â¾÷¿¡°Ô ¸Å¿ì Áß¿äÇÕ´Ï´Ù.

½ÃÀå ¿ªÇÐ : ºü¸£°Ô ÁøÈ­ÇÏ´Â µð¾Æº£¸®µò ½ÃÀåÀÇ ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ® Çظí

µð¾Æº£¸®µò ½ÃÀåÀº ¼ö¿ä ¹× °ø±ÞÀÇ ¿ªµ¿ÀûÀÎ »óÈ£ÀÛ¿ë¿¡ ÀÇÇØ º¯¸ðÇÏ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½ÃÀå ¿ªÇÐÀÇ ÁøÈ­¸¦ ÀÌÇØÇÔÀ¸·Î½á ±â¾÷Àº ÃæºÐÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÅõÀÚ°áÁ¤, Àü·«Àû °áÁ¤ Á¤¹ÐÈ­, »õ·Î¿î ºñÁî´Ï½º ±âȸ ȹµæ¿¡ ´ëºñÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ µ¿ÇâÀ» Á¾ÇÕÀûÀ¸·Î ÆľÇÇÔÀ¸·Î½á ±â¾÷Àº Á¤Ä¡Àû, Áö¸®Àû, ±â¼úÀû, »çȸÀû, °æÁ¦Àû ¿µ¿ª¿¡ °ÉÄ£ ´Ù¾çÇÑ ¸®½ºÅ©¸¦ °æ°¨ÇÒ ¼ö ÀÖÀ» »Ó¸¸ ¾Æ´Ï¶ó ¼ÒºñÀÚ Çൿ°ú ±×°ÍÀÌ Á¦Á¶ ºñ¿ë ¶Ç´Â ±¸¸Å µ¿Çâ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ»º¸´Ù ¸íÈ®ÇÏ°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • µð¾Æº£¸®µò ¹× °ü·Ã È­ÇÕ¹°¿¡ ÃÊÁ¡À» ¸ÂÃá R&D È°µ¿¿¡ ´ëÇÑ ÅõÀÚ Áõ°¡
    • Ãà»ê¾÷ È®´ë¿¡ ÀÇÇÑ È¿°úÀûÀÎ °¨¿°Á¦¾î ¼Ö·ç¼ÇÀÇ Çʿ伺
    • ´ÙÁ¦ ³»¼º ±â»ýÃæ Áõ°¡¿¡ ÀÇÇØ µð¾Æº£¸®µò°ú °°Àº °­·ÂÇÑ ´ëü¾à ¼ö¿ä°¡ ³ô¾ÆÁø´Ù
    • Á¦¾à±â¾÷ °£ÀÇ Àü·«Àû Á¦ÈÞ ¹× ÆÄÆ®³Ê½ÊÀ» ÅëÇÑ Á¦Ç° µµ´Þ ¹× Çõ½Å °­È­
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • µð¾Æº£¸®µòÀÇ »ç¿ë¿¡ ¼ö¹ÝÇϴ ȯ°æÀ̳ª °Ç°­¿¡ÀÇ ¾Ç¿µÇâ
    • µð¾Æº£¸®µò ½ÃÀå¿¡ ´ëÇÑ ÅõÀÚ¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â °æÁ¦ ºÒȲ°ú ½ÃÀå ȯ°æÀÇ º¯µ¿
  • ½ÃÀå ±âȸ
    • Áö¼Ó °¡´ÉÇÑ ³ó¾÷¿¡ ´ëÇÑ °ü½ÉÀÇ °íÁ¶°¡ µð¾Æº£¸®µò ½ÃÀåÀÇ ¼ºÀåÀ» µÞ¹Þħ
    • µð¾Æº£¸®µòÀÇ Á¾ÇÕÀû ÇØÃæ °ü¸® Àü·«¿¡ÀÇ Ã¤¿ë¿¡ ÀÇÇÑ ÀÜ·ù È­Çй°ÁúÀÇ »è°¨
    • ´ÙÁ¦ ³»¼º °¨¿°Áõ¿¡ ´ëÇÑ µð¾Æº£¸®µò ±â¹ÝÀÇ º´¿ë ¿ä¹ýÀÇ ¿¬±¸ °³¹ß
  • ½ÃÀåÀÇ °úÁ¦
    • µð¾Æº£¸®µò ½ÃÀåÀÇ ÁÖ¿ä ½ÃÀå °úÁ¦(Å×ÀÏ·¯ ¸ÞÀ̵å·Î ÃÖÀûÈ­µÈ °Í)
    • Å×ÀÏ·¯ ¸ÞÀ̵å·Î ÃÖÀûÈ­µÈ µð¾Æº£¸®µò ½ÃÀå¿¡ À־ÀÇ ¾÷°è ƯÀ¯ ½ÃÀå °úÁ¦

Porter's Five Forces : µð¾Æº£¸®µò ½ÃÀåÀ» Ž»öÇÏ´Â Àü·« µµ±¸

Porter's Five Forces Framework´Â Diaveridine ½ÃÀå °æÀï ±¸µµ¸¦ ÀÌÇØÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. Porter's Five Forces Framework´Â ±â¾÷ÀÇ °æÀï·ÂÀ» Æò°¡ÇÏ°í Àü·«Àû ±âȸ¸¦ Ž±¸ÇÏ´Â ¸íÈ®ÇÑ ±â¼úÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÌ ½ÃÀå ³» ¼¼·Âµµ¸¦ Æò°¡ÇÏ°í ½Å±Ô »ç¾÷ÀÇ ¼öÀͼºÀ» ÆÇ´ÜÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÀÌ·¯ÇÑ ÀλçÀÌÆ®À» ÅëÇØ ±â¾÷Àº ÀÚ»çÀÇ °­Á¡À» È°¿ëÇÏ°í, ¾àÁ¡À» ÇØ°áÇÏ°í, ÀáÀçÀûÀÎ °úÁ¦¸¦ ÇÇÇÒ ¼ö ÀÖÀ¸¸ç, º¸´Ù °­ÀÎÇÑ ½ÃÀå¿¡¼­ÀÇ Æ÷Áö¼Å´×À» º¸ÀåÇÒ ¼ö ÀÖ½À´Ï´Ù.

PESTLE ºÐ¼® : µð¾Æº£¸®µò ½ÃÀå¿¡¼­ ¿ÜºÎ·ÎºÎÅÍÀÇ ¿µÇâ ÆľÇ

¿ÜºÎ °Å½Ãȯ°æ ¿äÀÎÀº µð¾Æº£¸®µò ½ÃÀåÀÇ ¼º°ú ¿ªÇÐÀ» Çü¼ºÇϴµ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. Á¤Ä¡Àû, °æÁ¦Àû, »çȸÀû, ±â¼úÀû, ¹ýÀû, ȯ°æÀû ¿äÀÎ ºÐ¼®Àº ÀÌ·¯ÇÑ ¿µÇâÀ» Ž»öÇÏ´Â µ¥ ÇÊ¿äÇÑ Á¤º¸¸¦ Á¦°øÇÕ´Ï´Ù. PESTLE ¿äÀÎÀ» Á¶»çÇÔÀ¸·Î½á ±â¾÷Àº ÀáÀçÀûÀÎ À§Çè°ú ±âȸ¸¦ ´õ Àß ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®À» ÅëÇØ ±â¾÷Àº ±ÔÁ¦, ¼ÒºñÀÚ ¼±È£, °æÁ¦ µ¿ÇâÀÇ º¯È­¸¦ ¿¹ÃøÇÏ°í ¾ÕÀ¸·Î ¿¹»óµÇ´Â Àû±ØÀûÀÎ ÀÇ»ç °áÁ¤À» ÇÒ Áغñ¸¦ ÇÒ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå Á¡À¯À² ºÐ¼® Diaveridine ½ÃÀå °æÀï ±¸µµ ÆľÇ

µð¾Æº£¸®µò ½ÃÀåÀÇ »ó¼¼ÇÑ ½ÃÀå Á¡À¯À² ºÐ¼®À» ÅëÇØ °ø±Þ¾÷üÀÇ ¼º°ú¸¦ Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ±â¾÷Àº ¼öÀÍ, °í°´ ±â¹Ý, ¼ºÀå·ü µî ÁÖ¿ä ÁöÇ¥¸¦ ºñ±³ÇÏ¿© °æÀï Æ÷Áö¼Å´×À» ¹àÈú ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®À» ÅëÇØ ½ÃÀå ÁýÁß, ´ÜÆíÈ­, ÅëÇÕ µ¿ÇâÀ» ¹àÇô³»°í º¥´õµéÀº °æÀïÀÌ Ä¡¿­ÇØÁö´Â °¡¿îµ¥ ÀÚ»çÀÇ ÁöÀ§¸¦ ³ôÀÌ´Â Àü·«Àû ÀÇ»ç °áÁ¤À» ³»¸®´Â µ¥ ÇÊ¿äÇÑ Áö½ÄÀ» ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.

FPNV Positioning Matrix Diaveridine ½ÃÀå¿¡¼­ °ø±Þ¾÷üÀÇ ¼º´É Æò°¡

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º´Â µð¾Æº£¸®µò ½ÃÀå¿¡¼­ °ø±Þ¾÷ü¸¦ Æò°¡ÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ÀÌ Çà·ÄÀ» ÅëÇØ ºñÁî´Ï½º Á¶Á÷Àº °ø±Þ¾÷üÀÇ ºñÁî´Ï½º Àü·«°ú Á¦Ç° ¸¸Á·µµ¸¦ ±âÁØÀ¸·Î Æò°¡ÇÏ¿© ¸ñÇ¥¿¡ ¸Â´Â ÃæºÐÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÀÇ»ç °áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù. ³× °¡Áö »çºÐ¸éÀ» ÅëÇØ °ø±Þ¾÷ü¸¦ ¸íÈ®ÇÏ°í Á¤È®ÇÏ°Ô ºÎ¹®È­ÇÏ°í Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê ¹× ¼Ö·ç¼ÇÀ» ÆľÇÇÒ ¼ö ÀÖ½À´Ï´Ù.

Àü·«ºÐ¼®°ú Ãßõ µð¾Æº£¸®µò ½ÃÀå¿¡¼­ ¼º°øÀ» À§ÇÑ ±æÀ» ±×¸®±â

µð¾Æº£¸®µò ½ÃÀåÀÇ Àü·« ºÐ¼®Àº ½ÃÀå¿¡¼­ÀÇ ÇÁ·¹Á𽺠°­È­¸¦ ¸ñÇ¥·Î ÇÏ´Â ±â¾÷¿¡ ÇʼöÀûÀÔ´Ï´Ù. ÁÖ¿ä ÀÚ¿ø, ¿ª·® ¹× ¼º°ú ÁöÇ¥¸¦ °ËÅäÇÔÀ¸·Î½á ±â¾÷Àº ¼ºÀå ±âȸ¸¦ ÆľÇÇÏ°í °³¼±À» À§ÇØ ³ë·ÂÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Á¢±Ù ¹æ½ÄÀ» ÅëÇØ °æÀï ±¸µµ¿¡¼­ °úÁ¦¸¦ ±Øº¹ÇÏ°í »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ È°¿ëÇÏ¿© Àå±âÀûÀÎ ¼º°øÀ» °ÅµÑ ¼ö Àִ üÁ¦¸¦ ±¸ÃàÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­´Â ÁÖ¿ä °ü½É ºÐ¾ß¸¦ Æ÷°ýÇÏ´Â ½ÃÀåÀÇ Á¾ÇÕÀûÀÎ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

1. ½ÃÀå ħÅõ : ÇöÀç ½ÃÀå ȯ°æÀÇ »ó¼¼ÇÑ °ËÅä, ÁÖ¿ä ±â¾÷ÀÇ ±¤¹üÀ§ÇÑ µ¥ÀÌÅÍ, ½ÃÀå µµ´Þ¹üÀ§ ¹× Àü¹ÝÀûÀÎ ¿µÇâ·Â Æò°¡.

2. ½ÃÀå °³Ã´µµ : ½ÅÈï ½ÃÀåÀÇ ¼ºÀå ±âȸ¸¦ ÆľÇÇÏ°í ±âÁ¸ ºÐ¾ßÀÇ È®Àå °¡´É¼ºÀ» Æò°¡ÇÏ¸ç ¹Ì·¡ ¼ºÀåÀ» À§ÇÑ Àü·«Àû ·Îµå¸ÊÀ» Á¦°øÇÕ´Ï´Ù.

3. ½ÃÀå ´Ù¾çÈ­ : ÃÖ±Ù Á¦Ç° Ãâ½Ã, ¹Ì°³Ã´ Áö¿ª, ¾÷°èÀÇ ÁÖ¿ä Áøº¸, ½ÃÀåÀ» Çü¼ºÇÏ´Â Àü·«Àû ÅõÀÚ¸¦ ºÐ¼®ÇÕ´Ï´Ù.

4. °æÀï Æò°¡ ¹× Á¤º¸ : °æÀï ±¸µµ¸¦ öÀúÈ÷ ºÐ¼®ÇÏ¿© ½ÃÀå Á¡À¯À², »ç¾÷ Àü·«, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÀÎÁõ, ±ÔÁ¦ ´ç±¹ ½ÂÀÎ, ƯÇã µ¿Çâ, ÁÖ¿ä ±â¾÷ÀÇ ±â¼ú Áøº¸ µîÀ» °ËÁõÇÕ´Ï´Ù.

5. Á¦Ç° °³¹ß ¹× Çõ½Å : ¹Ì·¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÃÖ÷´Ü ±â¼ú, R&D È°µ¿, Á¦Ç° Çõ½ÅÀ» °­Á¶ÇÕ´Ï´Ù.

¶ÇÇÑ ÀÌÇØ°ü°èÀÚ°¡ ÃæºÐÇÑ Á¤º¸¸¦ ¾ò°í ÀÇ»ç°áÁ¤À» ÇÒ ¼ö ÀÖµµ·Ï Áß¿äÇÑ Áú¹®¿¡ ´ë´äÇÏ°í ÀÖ½À´Ï´Ù.

1. ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÇâÈÄ ¼ºÀå ¿¹ÃøÀº?

2. ÃÖ°íÀÇ ÅõÀÚ ±âȸ¸¦ Á¦°øÇÏ´Â Á¦Ç°, ºÎ¹® ¹× Áö¿ªÀº ¾îµðÀԴϱî?

3. ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ±â¼ú µ¿Çâ°ú ±ÔÁ¦ÀÇ ¿µÇâÀº?

4. ÁÖ¿ä º¥´õÀÇ ½ÃÀå Á¡À¯À²°ú °æÀï Æ÷Áö¼ÇÀº?

5. º¥´õ ½ÃÀå ÁøÀÔ, ö¼ö Àü·«ÀÇ ¿øµ¿·ÂÀÌ µÇ´Â ¼öÀÍ¿ø°ú Àü·«Àû ±âȸ´Â ¹«¾ùÀΰ¡?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå °³¿ä

Á¦5Àå ½ÃÀå ÀλçÀÌÆ®

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
      • µð¾Æº£¸®µò ¹× °ü·Ã È­ÇÕ¹°¿¡ ÃÊÁ¡À» ¸ÂÃá R&D È°µ¿¿¡ ´ëÇÑ ÅõÀÚ Áõ°¡
      • Ãà»ê¾÷ È®´ë·Î È¿°úÀûÀÎ °¨¿°Á¦¾î ¼Ö·ç¼ÇÀÇ Çʿ伺ÀÌ ³ô¾ÆÁö°í ÀÖ´Ù
      • ´ÙÁ¦ ³»¼º ±â»ýÃæ Áõ°¡·Î µð¾Æº£¸®µò°ú °°Àº °­·ÂÇÑ ´ëüǰ¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÏ°í ÀÖ½À´Ï´Ù.
      • ÀǾàÇ° ±â¾÷ °£ÀÇ Àü·«Àû Çù¾÷°ú ÆÄÆ®³Ê½ÊÀ» ÅëÇØ Á¦Ç°ÀÇ º¸±Þ°ú Çõ½ÅÀ» ÃËÁø
    • ¾ïÁ¦¿äÀÎ
      • µð¾Æº£¸®µòÀÇ »ç¿ë°ú °ü·ÃµÈ ȯ°æ ¹× °Ç°­¿¡ ´ëÇÑ ¾Ç¿µÇâ
      • °æÁ¦ ħü¿Í ½ÃÀå »óȲÀÇ º¯µ¿ÀÌ µð¾Æº£¸®µò ½ÃÀå¿¡ ´ëÇÑ ÅõÀÚ¿¡ ¿µÇâ
    • ±âȸ
      • Áö¼Ó °¡´ÉÇÑ ³ó¾÷¿¡ ´ëÇÑ °ü½ÉÀÇ °íÁ¶°¡ µð¾Æº£¸®µò ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼Ó
      • È­Çй°Áú ÀÜ·ù¹°À» »è°¨Çϱâ À§ÇÑ Á¾ÇÕÀû ÇØÃæ °ü¸® Àü·«¿¡ À־ÀÇ µð¾Æº£¸®µòÀÇ Ã¤¿ë
      • ´ÙÁ¦ ³»¼º °¨¿°Áõ¿¡ ´ëÇÑ µð¾Æº£¸®µòÀ» º£À̽º·Î ÇÑ º´¿ë ¿ä¹ýÀÇ ¿¬±¸ °³¹ß
    • °úÁ¦
      • ¸ÂÃãÇü ÃÖÀûÈ­µÈ µð¾Æº£¸®µò ½ÃÀåÀÇ ÁÖ¿ä ½ÃÀå °úÁ¦
      • ¸ÂÃãÇü ÃÖÀûÈ­µÈ µð¾Æº£¸®µò ½ÃÀå¿¡¼­ÀÇ ¾÷°è °íÀ¯ ½ÃÀå °úÁ¦
  • ½ÃÀå ¼¼ºÐÈ­ ºÐ¼®
  • Porter's Five Forces ºÐ¼®
  • PESTEL ºÐ¼®
    • Á¤Ä¡Àû
    • °æÁ¦
    • »ç±³
    • ±â¼úÀû
    • ¹ý·ü»ó
    • ȯ°æ

Á¦6Àå µð¾Æº£¸®µò ½ÃÀå : Á¦Ç° À¯Çüº°

  • ¾×ü ÇüÅÂ
    • ¼Ö·ç¼Ç
    • ¼­½ºÆæ¼Ç
  • ¼Ö¸®µå Æû
    • ĸ½¶
    • ÅÂºí¸´

Á¦7Àå µð¾Æº£¸®µò ½ÃÀå : ¿ëµµº°

  • Àΰ£ ÀÇÇÐ
    • Ç×°¨¿°
    • º´¿ë ¿ä¹ý
  • ¼öÀÇÇÐ
    • ¼Ò
    • °¡±Ý·ù
    • µÅÁö

Á¦8Àå µð¾Æº£¸®µò ½ÃÀå : ÃÖÁ¾ »ç¿ëÀÚº°

  • º´¿ø
    • »ç¸³º´¿ø
    • °ø¸³º´¿ø
  • ¼öÀÇ»ç Ŭ¸®´Ð
    • Áö¹æÀÇ Áø·á¼Ò
    • ¾î¹Ý Ŭ¸®´Ð

Á¦9Àå µð¾Æº£¸®µò ½ÃÀå : À¯Åë ä³Îº°

  • Á÷Á¢ ÆǸÅ
    • ÇコÄɾî Á¾»çÀÚ ¿©·¯ºÐ¿¡°Ô
  • ¸®¼¿·¯
    • ¼Ò¸Å ¾à±¹
    • µµ¸Å¾÷ü

Á¦10Àå ¾Æ¸Þ¸®Ä«ÀÇ µð¾Æº£¸®µò ½ÃÀå

  • ¾Æ¸£ÇîƼ³ª
  • ºê¶óÁú
  • ij³ª´Ù
  • ¸ß½ÃÄÚ
  • ¹Ì±¹

Á¦11Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ µð¾Æº£¸®µò ½ÃÀå

  • È£ÁÖ
  • Áß±¹
  • Àεµ
  • Àεµ³×½Ã¾Æ
  • ÀϺ»
  • ¸»·¹À̽þÆ
  • Çʸ®ÇÉ
  • ½Ì°¡Æ÷¸£
  • Çѱ¹
  • ´ë¸¸
  • ű¹
  • º£Æ®³²

Á¦12Àå À¯·´, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ µð¾Æº£¸®µò ½ÃÀå

  • µ§¸¶Å©
  • ÀÌÁýÆ®
  • Çɶõµå
  • ÇÁ¶û½º
  • µ¶ÀÏ
  • À̽º¶ó¿¤
  • ÀÌÅ»¸®¾Æ
  • ³×´ú¶õµå
  • ³ªÀÌÁö¸®¾Æ
  • ³ë¸£¿þÀÌ
  • Æú¶õµå
  • īŸ¸£
  • ·¯½Ã¾Æ
  • »ç¿ìµð¾Æ¶óºñ¾Æ
  • ³²¾ÆÇÁ¸®Ä«
  • ½ºÆäÀÎ
  • ½º¿þµ§
  • ½ºÀ§½º
  • ÅÍÅ°
  • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
  • ¿µ±¹

Á¦13Àå °æÀï ±¸µµ

  • ½ÃÀå Á¡À¯À² ºÐ¼®(2023³â)
  • FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º(2023³â)
  • °æÀï ½Ã³ª¸®¿À ºÐ¼®
  • Àü·« ºÐ¼®°ú Á¦¾È

±â¾÷ ¸ñ·Ï

  • 1. AlzChem Group AG
  • 2. BASF SE
  • 3. Bayer AG
  • 4. Covenant Chemical, Inc.
  • 5. Evonik Industries AG
  • 6. Fengchen Group Co., Ltd.
  • 7. Haihang Industry Co., Ltd.
  • 8. Hefei TNJ Chemical Industry Co., Ltd.
  • 9. HELM AG
  • 10. Henan CoreyChem Co., Ltd.
  • 11. Jiangsu World Chemical Industry Co., Ltd.
  • 12. LANXESS AG
  • 13. Lonza Group AG
  • 14. Meryer(Shanghai) Chemical Technology Co., Ltd.
  • 15. Oxea GmbH
  • 16. Shandong Xinhua Pharmaceutical Co., Ltd.
  • 17. Simagchem Corporation
  • 18. Taizhou Creating Chemical Co., Ltd.
  • 19. Toronto Research Chemicals
  • 20. Zhejiang Xinhua Chemical Co., Ltd.
BJH 24.11.07

The Diaveridine Market was valued at USD 234.45 million in 2023, expected to reach USD 255.38 million in 2024, and is projected to grow at a CAGR of 9.35%, to USD 438.49 million by 2030.

Diaveridine, a veterinary drug primarily used as an antiprotozoal agent in livestock, plays a crucial role in animal health by inhibiting folic acid synthesis in parasites, making it effective against coccidiosis and other protozoal infections. The necessity of diaveridine arises from the pressing need to maintain livestock health and productivity, particularly given the ever-increasing demand for animal protein. Its application spans across poultry, swine, and cattle industries, with farmers and veterinarians relying on it to prevent and control protozoal diseases, ultimately ensuring efficient meat and dairy production. The end-use scope is notably vast in regions with intensive livestock farming practices, such as North America, Europe, and APAC, particularly in China and India, where rapid urbanization fuels meat consumption.

KEY MARKET STATISTICS
Base Year [2023] USD 234.45 million
Estimated Year [2024] USD 255.38 million
Forecast Year [2030] USD 438.49 million
CAGR (%) 9.35%

Market insights reveal that key factors influencing the growth of the Diaveridine market include the burgeoning global meat demand, advancements in veterinary medicine, and increasing awareness of animal welfare. Technological integration in agriculture also aids in precise drug administration, enhancing efficacy and compliance with dosage specifications. Currently, potential opportunities lie in expanding the portfolio of combination drugs-pairing diaveridine with other agents to combat drug resistance-alongside exploring its benefits in lesser-utilized livestock sectors. Capturing these opportunities involves investing in research and development (R&D) and fostering partnerships with agricultural institutes to innovate solutions that address resistance challenges and harness synergistic effects.

However, market growth is tempered by stringent regulatory controls and public health concerns, with antimicrobial resistance garnering significant attention. Additionally, increasing consumer trends towards organic and antibiotic-free meat pose challenges. Innovations in the diaveridine market could focus on sustainable drug formulation, microencapsulation to enhance absorption, and bio-based alternatives that abide by organic farming regulations. Understanding these dynamics is crucial for businesses aiming to secure a foothold in a competitive market characterized by evolving regulatory landscapes and consumer preferences.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Diaveridine Market

The Diaveridine Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing investment in research and development activities focused on diaveridine and related compounds
    • Expansion of the livestock industry driving the need for effective infection control solutions
    • The rise in multi-drug resistant parasites creating demand for potent alternatives like diaveridine
    • Strategic collaborations and partnerships between pharmaceutical companies to enhance product reach and innovation
  • Market Restraints
    • Adverse environmental and health impacts associated with diaveridine usage
    • Economic downturns and fluctuating market conditions impacting diaveridine market investments
  • Market Opportunities
    • Growing emphasis on sustainable agriculture fueling Diaveridine market growth
    • Adoption of Diaveridine in integrated pest management strategies to reduce chemical residues
    • Research and development in Diaveridine-based combination therapies for multidrug-resistant infections
  • Market Challenges
    • Primary market challenges in the Diaveridine Market that are tailored and optimized
    • Industry-specific market challenges in the Diaveridine Market that are tailored and optimized

Porter's Five Forces: A Strategic Tool for Navigating the Diaveridine Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Diaveridine Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Diaveridine Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Diaveridine Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Diaveridine Market

A detailed market share analysis in the Diaveridine Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Diaveridine Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Diaveridine Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Diaveridine Market

A strategic analysis of the Diaveridine Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Diaveridine Market, highlighting leading vendors and their innovative profiles. These include AlzChem Group AG, BASF SE, Bayer AG, Covenant Chemical, Inc., Evonik Industries AG, Fengchen Group Co., Ltd., Haihang Industry Co., Ltd., Hefei TNJ Chemical Industry Co., Ltd., HELM AG, Henan CoreyChem Co., Ltd., Jiangsu World Chemical Industry Co., Ltd., LANXESS AG, Lonza Group AG, Meryer (Shanghai) Chemical Technology Co., Ltd., Oxea GmbH, Shandong Xinhua Pharmaceutical Co., Ltd., Simagchem Corporation, Taizhou Creating Chemical Co., Ltd., Toronto Research Chemicals, and Zhejiang Xinhua Chemical Co., Ltd..

Market Segmentation & Coverage

This research report categorizes the Diaveridine Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product Type, market is studied across Liquid Form and Solid Form. The Liquid Form is further studied across Solution and Suspension. The Solid Form is further studied across Capsules and Tablets.
  • Based on Application, market is studied across Human Medicine and Veterinary Medicine. The Human Medicine is further studied across Anti-Infective and Combination Therapy. The Veterinary Medicine is further studied across Cattle, Poultry, and Swine.
  • Based on End User, market is studied across Hospitals and Veterinary Clinics. The Hospitals is further studied across Private Hospitals and Public Hospitals. The Veterinary Clinics is further studied across Rural Clinics and Urban Clinics.
  • Based on Distribution Channel, market is studied across Direct Sales and Distributors. The Direct Sales is further studied across To Healthcare Providers. The Distributors is further studied across Retail Pharmacies and Wholesalers.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing investment in research and development activities focused on diaveridine and related compounds
      • 5.1.1.2. Expansion of the livestock industry driving the need for effective infection control solutions
      • 5.1.1.3. The rise in multi-drug resistant parasites creating demand for potent alternatives like diaveridine
      • 5.1.1.4. Strategic collaborations and partnerships between pharmaceutical companies to enhance product reach and innovation
    • 5.1.2. Restraints
      • 5.1.2.1. Adverse environmental and health impacts associated with diaveridine usage
      • 5.1.2.2. Economic downturns and fluctuating market conditions impacting diaveridine market investments
    • 5.1.3. Opportunities
      • 5.1.3.1. Growing emphasis on sustainable agriculture fueling Diaveridine market growth
      • 5.1.3.2. Adoption of Diaveridine in integrated pest management strategies to reduce chemical residues
      • 5.1.3.3. Research and development in Diaveridine-based combination therapies for multidrug-resistant infections
    • 5.1.4. Challenges
      • 5.1.4.1. Primary market challenges in the Diaveridine Market that are tailored and optimized
      • 5.1.4.2. Industry-specific market challenges in the Diaveridine Market that are tailored and optimized
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Diaveridine Market, by Product Type

  • 6.1. Introduction
  • 6.2. Liquid Form
    • 6.2.1. Solution
    • 6.2.2. Suspension
  • 6.3. Solid Form
    • 6.3.1. Capsules
    • 6.3.2. Tablets

7. Diaveridine Market, by Application

  • 7.1. Introduction
  • 7.2. Human Medicine
    • 7.2.1. Anti-Infective
    • 7.2.2. Combination Therapy
  • 7.3. Veterinary Medicine
    • 7.3.1. Cattle
    • 7.3.2. Poultry
    • 7.3.3. Swine

8. Diaveridine Market, by End User

  • 8.1. Introduction
  • 8.2. Hospitals
    • 8.2.1. Private Hospitals
    • 8.2.2. Public Hospitals
  • 8.3. Veterinary Clinics
    • 8.3.1. Rural Clinics
    • 8.3.2. Urban Clinics

9. Diaveridine Market, by Distribution Channel

  • 9.1. Introduction
  • 9.2. Direct Sales
    • 9.2.1. To Healthcare Providers
  • 9.3. Distributors
    • 9.3.1. Retail Pharmacies
    • 9.3.2. Wholesalers

10. Americas Diaveridine Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Diaveridine Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Diaveridine Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AlzChem Group AG
  • 2. BASF SE
  • 3. Bayer AG
  • 4. Covenant Chemical, Inc.
  • 5. Evonik Industries AG
  • 6. Fengchen Group Co., Ltd.
  • 7. Haihang Industry Co., Ltd.
  • 8. Hefei TNJ Chemical Industry Co., Ltd.
  • 9. HELM AG
  • 10. Henan CoreyChem Co., Ltd.
  • 11. Jiangsu World Chemical Industry Co., Ltd.
  • 12. LANXESS AG
  • 13. Lonza Group AG
  • 14. Meryer (Shanghai) Chemical Technology Co., Ltd.
  • 15. Oxea GmbH
  • 16. Shandong Xinhua Pharmaceutical Co., Ltd.
  • 17. Simagchem Corporation
  • 18. Taizhou Creating Chemical Co., Ltd.
  • 19. Toronto Research Chemicals
  • 20. Zhejiang Xinhua Chemical Co., Ltd.
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óÇ°À» ¼±Åà Áß
»óÇ° ºñ±³Çϱâ
Àüü»èÁ¦